Your trusted source for investing success

Tag: patient

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

Q BioMed Announces Development Partnership With Sphaera Pharma

Q BioMed Announces Development Partnership With Sphaera Pharma

Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.

 “The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers

Hydropothecary Announces Kosher Certification on Processed Medical Marijuana Products

Hydropothecary Announces Kosher Certification on Processed Medical Marijuana Products

The Hydropothecary Corporation (“THCX” or the “Company”) (TSXV:THCX) is pleased to announce its processed medical marijuana products have been granted kosher certification by the Ottawa Vaad HaKashrut. It is the only kosher certification currently granted to cannabis products in Canada.

The kosher certification, includes Decarb, the ready-to-consume activated marijuana powder product

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/delmar-pharmaceuticals-announces-issuance-new-patent-first-class-dna-targeting-agent-val-083/